Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin

被引：10

作者：

Isoda, Atsushi ^{[1
,2
]}

Miyazawa, Yuri ^{[1
]}

Tahara, Kenichi ^{[1
]}

Mihara, Masahiro ^{[1
]}

Saito, Akio ^{[1
]}

Matsumoto, Morio ^{[1
]}

Sawamura, Morio ^{[1
]}

机构：

[1] Natl Hosp Org Shibukawa Med Ctr, Dept Hematol, Shibukawa, Gunma, Japan

[2] Hoshi Clin, Dept Hematol, Sapporo, Hokkaido, Japan

来源：

INTERNAL MEDICINE | 2020年 / 59卷 / 16期

关键词：

pure red cell aplasia; pembrolizumab; programed cell death 1; immune-related adverse events; direct anti-globulin test; intravenous immunoglobulin; AUTOIMMUNE HEMOLYTIC-ANEMIA; IMMUNOTHERAPY; RITUXIMAB; LYMPHOMA;

D O I：

10.2169/internalmedicine.4467-20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We herein report a 64-year-old man who was treated with pembrolizumab for relapsed Hodgkin lymphoma. After the third administration of pembrolizumab, he showed acute anemia with a positive direct antiglobulin test. Because of the markedly erythroid hypoplasia, he was diagnosed with pure red cell aplasia (PRCA) caused by pembrolizumab. He was initially treated with prednisolone, but the reticulocytes decreased after tapering prednisolone. He then received high-dose intravenous immunoglobulin (WIG) with prednisolone, and PRCA was successfully treated. Although the pathogenesis of PRCA caused by immune checkpoint inhibitors (CPIs) remains unclear, WIG treatment may be effective for some steroid-refractory CPI-induced PRCA cases.

引用

页码：2041 / 2045

页数：5

共 28 条

[1] Primary Sjogren syndrome complicated by autoimmune hemolytic cell aplasia
Assimakopoulos, Stelios F.
Michalopoulou, Sotiria
Melachrinou, Maria
Giannakoulas, Nikolaos
Papakonstantinou, Christos
Lekkou, Alexandra
Gogos, Charalambos
[J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 334 (06) : 493 - 496
[2] BJORKHOLM M, 1993, J INTERN MED, V234, P119
[3] IVIg treatment of pemphigus: How it works & how to use it
Bystryn, JC
Rudolph, JL
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) : 1093 - 1098
[4] TREATMENT OF PURE RED-CELL APLASIA BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS
CLAUVEL, JP
VAINCHENKER, W
HERRERA, A
DELLAGI, K
VINCI, G
TABILIO, A
LACOMBE, C
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1983, 55 (02) : 380 - 382
[5] Rituximab in the treatment of pembrolizumab-induced myasthenia gravis
Crusz, S. M.
Radunovic, A.
Shepherd, S.
Shah, S.
Newey, V.
Phillips, M.
Lim, L.
Powles, T.
Szlosarek, P. W.
Shamash, J.
Rashid, S.
[J]. EUROPEAN JOURNAL OF CANCER, 2018, 102 : 49 - 51
[6] Hematologic Complications of Immune Checkpoint Inhibitors
Davis, Elizabeth J.
Salem, Joe-Elie
Young, Arissa
Green, Jennifer R.
Ferrell, P. Brent
Ancell, Kristin K.
Lebrun-Vignes, Benedicte
Moslehi, Javid J.
Johnson, Douglas B.
[J]. ONCOLOGIST, 2019, 24 (05) : 584 - 588
[7] Delaney N, 2019, LANCET HAEMATOL, V6, pE48, DOI [10.1016/S2352-3026(18)30175-3, 10.1016/52352-3026(18)30175-3]
[8] Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab
Gokozan, Hamza N.
Friedman, Judah D.
Schmaier, Alvin H.
Downes, Katharine A.
Farah, Lisa A.
Reeves, Hollie M.
[J]. CLINICAL LUNG CANCER, 2019, 20 (05) : E560 - E563
[9] Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Gordon, Ilyssa O.
Wade, Takisha
Chin, Kevin
Dickstein, Jerome
Gajewski, Thomas F.
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) : 1351 - 1353
[10] Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors
Handgretinger, R
Geiselhart, A
Moris, A
Grau, R
Teuffel, O
Bethge, W
Kanz, L
Fisch, P
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) : 278 - 284

← 1 2 3 →